Item 5.02 Departure of Directors or Certain Officers; Election of Directors;


           Appointment of Certain Officers; Compensatory Arrangement of Certain
           Officers


 Appointment of Director

On January 6, 2022, the Board of Directors of Emmaus Life Sciences, Inc. ("we," "us," "our," "Emmaus" or the "company") expanded the number of directors from seven to eight and appointed Lori Teranishi as a director of the company. Ms. Teranishi is also expected to be appointed to serve on one or more of the standing Committees of the Board when her schedule permits.

Ms. Teranishi is the founder and Chief Executive Officer of iQ 360, a privately held strategic communications company with offices in Honolulu, San Francisco, New York and Washington DC, whose clients include business leaders, global corporations, innovative startups, nonprofits, and government agencies. She is an expert in business consulting, crisis communications, issues management, corporate positioning, and marketing strategy. She has a successful track record repositioning brands, launching, and executing major change initiatives, counseling companies in the sustainability and ESG (environmental, social, and corporate governance) space and protecting reputations in the face of high-profile litigation, mass company layoffs and regulatory investigations. Before founding iQ 360 in 2010, Ms. Teranishi oversaw product development as a vice president at Visa, where she launched a global loyalty program and other consumer and B2B products. She also served as chief of staff to Visa's chief operating officer, managing business planning for the company, and prior to that role, had responsibility for variety of communications functions. Ms. Teranishi holds bachelor's degrees in mass communications and political science from the University of Utah and earned her MBA from the University of San Francisco. Ms. Teranishi was named a Ragan's Top Woman Leader in Communications in 2020 and received a Distinguished Alumni Award from the University of Utah in 2019.

Ms. Teranishi will receive the same compensation as our other non-employee directors and members of any Board Committee to which she may be appointed as described under the caption "Executive Compensation - Current Director Compensation" in our definitive Proxy Statement filed with the Securities and Exchange Commission ("SEC") on October 12, 2021 and incorporated herein by reference. It is expected that she also will enter into our standard-form of indemnification agreement for directors and executive officers which appears as an exhibit to our Annual Report on Form 10-K/A filed with the SEC on August 10, 2021. As with our other directors, Ms. Teranishi will serve as a director until her successor is elected and qualified or her resignation, disqualification or removal.

There are no family relationships between Ms. Teranishi and any of our other directors, executive officers, or persons nominated or chosen to become a director or executive officer. Ms. Teranishi is not a party to any current or proposed transaction for which disclosure is required under Item 404(a) of Regulation S-K.


                                       1

© Edgar Online, source Glimpses